Willis Investment Counsel Has $18.98 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Willis Investment Counsel boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 0.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 888,983 shares of the company’s stock after acquiring an additional 5,231 shares during the quarter. Willis Investment Counsel’s holdings in Kenvue were worth $18,980,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. U.S. Capital Wealth Advisors LLC boosted its position in Kenvue by 5.6% during the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 29,298 shares of the company’s stock worth $626,000 after acquiring an additional 1,551 shares during the period. Golden State Equity Partners boosted its position in Kenvue by 716.1% during the 4th quarter. Golden State Equity Partners now owns 25,658 shares of the company’s stock worth $548,000 after acquiring an additional 22,514 shares during the period. Spire Wealth Management acquired a new stake in Kenvue during the 4th quarter worth about $95,000. DAVENPORT & Co LLC lifted its holdings in shares of Kenvue by 0.4% during the 4th quarter. DAVENPORT & Co LLC now owns 388,684 shares of the company’s stock valued at $8,268,000 after buying an additional 1,679 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Kenvue by 5.6% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 57,578 shares of the company’s stock valued at $1,229,000 after buying an additional 3,028 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on KVUE shares. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $21.00 to $26.00 in a report on Monday, January 6th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. UBS Group reduced their price target on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, January 16th. Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Finally, JPMorgan Chase & Co. lifted their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Kenvue has an average rating of “Hold” and an average price target of $23.08.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $21.29 on Monday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $21.90 and its two-hundred day moving average is $21.92. The company has a market cap of $40.82 billion, a P/E ratio of 38.71, a P/E/G ratio of 2.05 and a beta of 1.45. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the previous year, the business posted $0.31 EPS. On average, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.85%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.